Heart failure is an under-recognised complication of T2D
Data from the Landmark DAPA-HF Trial***
In both study arms, treatment was on top of standard of care.
Forxiga also lowers HbA1c with additional benefits of weight
and blood pressure reduction vs Placebo11#
HbA1c reductions of -0.84% from baseline at 24 weeks11
-2.9 kg weight loss from baseline at 24 weeks11#
-5.1 mmHg systolic blood pressure reduction from baseline at 24 weeks11#
Safety and tolerability
When prescribing in patients with co-morbid symptomatic HFrEF and insufficiently controlled T2D1
Simple once-daily dosing§§, no dose adjustment required based on renal function.
§§ No dose adjustment is necessary for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, the dose may be increased to 10 mg1